Correlation Between Arcus Biosciences and Spyre Therapeutics
Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcus Biosciences and Spyre Therapeutics, you can compare the effects of market volatilities on Arcus Biosciences and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Spyre Therapeutics.
Diversification Opportunities for Arcus Biosciences and Spyre Therapeutics
0.24 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Arcus and Spyre is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Spyre Therapeutics go up and down completely randomly.
Pair Corralation between Arcus Biosciences and Spyre Therapeutics
Given the investment horizon of 90 days Arcus Biosciences is expected to generate 0.87 times more return on investment than Spyre Therapeutics. However, Arcus Biosciences is 1.15 times less risky than Spyre Therapeutics. It trades about 0.14 of its potential returns per unit of risk. Spyre Therapeutics is currently generating about -0.18 per unit of risk. If you would invest 1,456 in Arcus Biosciences on September 24, 2024 and sell it today you would earn a total of 140.00 from holding Arcus Biosciences or generate 9.62% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Arcus Biosciences vs. Spyre Therapeutics
Performance |
Timeline |
Arcus Biosciences |
Spyre Therapeutics |
Arcus Biosciences and Spyre Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Arcus Biosciences and Spyre Therapeutics
The main advantage of trading using opposite Arcus Biosciences and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.Arcus Biosciences vs. Cullinan Oncology LLC | Arcus Biosciences vs. Annexon | Arcus Biosciences vs. Structure Therapeutics American | Arcus Biosciences vs. Relay Therapeutics |
Spyre Therapeutics vs. Fate Therapeutics | Spyre Therapeutics vs. Sana Biotechnology | Spyre Therapeutics vs. Caribou Biosciences | Spyre Therapeutics vs. Arcus Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Complementary Tools
CEOs Directory Screen CEOs from public companies around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |